tbuckley/cabot-search huggingface dataset:
FRI0588 DIAGNOSTIC PERFORMANCE OF THE RHEUMATOID FACTOR ISOTYPES IN RHEUMATIC DISEASES
Authors: R. Pineda-Sic, D. Vega-Morales, L. Santoyo-Fexas, M. M. Castañeda-Martínez, I. D. J. Hernandez-Galarza, M. A. Villarreal-Alarcón, J. C. Riegatorres, L. Pérez Barbosa, D. E. Flores Alvarado, M. Eguia Bernal, G. Serna-Peña, D. Á. Galarza-Delgado
Journal: Annals of the Rheumatic Diseases (2020)

Background: Rheumatoid Factor (RF) is used for the classification of Rheumatoid arthritis (RA) in patients whose main complaint is hand arthritis but is well known that other conditions have positive RF. Differences in analytical performance between assays were found in previous studies, there was a poor numerical agreement, and using the cut-off proposed by the manufacturer, variation in sensitivity and specificity can be seen. 2 Objectives: To determine the cut-off value for RF with the best diagnostic performance for RA in patients with hand arthritis compared with their main differential diagnoses. Methods: Descriptive, cross-sectional, diagnostic test study. Sampling size was calculated 2:1, with the area under the ROC curve (AUC): 0.708, power 80% and significance 0.05. Patients with RA, Systemic Lupus Erythematosus (SLE), Osteoarthritis (OA), fibromyalgia (FBM), Polyarticular Gout (PG), Psoriatic Arthritis(Psa), Sjögren Syndrome (SS), Arthralgia suspicious for progression to RA (ASP) and healthy subjects, previously classified with the current criteria by certified rheumatologist were included. EUROINMMUN ® assays for RF isotypes IgA, IgM, IgG were used. ROC curves and Youden index for determining the cut-off with the best sensitivity and specificity for each RF isotype comparing RA with other diseases were used. Statistical analyses were performed with SPSS V.24. Results: Three hundred and thirty-two serum samples from patients were included, in the other rheumatic diseases different from RA, we found positive RF IgM in 141 (45.5%), 82 (26.5%) IgA and 25 (8.1%) IgG. For each clinical scenario the cut-off with the best sensitivity and specificity was different from the manufacturer proposed, and isotypes with the best diagnostic performance was not the same for each disease, Table 1. We present the ROC curve for RF isotypes in Figure 1. Conclusion: In order to improve the diagnosis of Rheumatoid Arthritis, different cut-off points of RF and isotypes should be used. References: [1] Van Hoovels L, Jacobs J, Vander Cruyssen B, Van Den Bremt S, Verschueren P, Bossuyt X. Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis. Ann Rheum Dis. 2018;77(5):667-677. doi:10.1136/annrheumdis-2017-212365 [2] Van Boekel MAM, Vossenaar ER, Van Den Hoogen FHJ, Van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res. 2002;4(2):87-93. doi:10.1186/ar395. Disclosure of Interests: None declared
Comprehensive Analysis of Radiomic Datasets by RadAR
Authors: Matteo Benelli, Andrea Barucci, Nicola Zoppetti, Silvia Calusi, Laura Redapi, Giuseppe Della Gala, Stefano Piffer, Luca Bernardi, Franco Fusi, Stefania Pallotta
Journal: Cancer Research (2020)

Quantitative analysis of biomedical images, referred to as radiomics, is emerging as a promising approach to facilitate clinical decisions and improve patient stratification. The typical radiomic workflow includes image acquisition, segmentation, feature extraction, and analysis of high-dimensional datasets. While procedures for primary radiomic analyses have been established in recent years, processing the resulting radiomic datasets remains a challenge due to the lack of specific tools for doing so. Here we present RadAR (Radiomics Analysis with R), a new software to perform comprehensive analysis of radiomic features. RadAR allows users to process radiomic datasets in their entirety, from data import to feature processing and visualization, and implements multiple statistical methods for analysis of these data. We used RadAR to analyze the radiomic profiles of more than 850 patients with cancer from publicly available datasets and showed that it was able to recapitulate expected results. These results demonstrate RadAR as a reliable and valuable tool for the radiomics community. SIGNIFICANCE: A new computational tool performs comprehensive analysis of high-dimensional radiomic datasets, recapitulating expected results in the analysis of radiomic profiles of >850 patients with cancer from independent datasets.
Genotyping SARS-CoV-2 through an interactive web application
Authors: Hassaan Maan, Hamza Mbareche, Amogelang R Raphenya, Arinjay Banerjee, Jalees A Nasir, Robert A Kozak, Natalie Knox, Samira Mubareka, Andrew G McArthur, Bo Wang
Journal: The Lancet Digital Health (2020)
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Authors: Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, Matthew A Cavender, Anna Norhammar, Marit E Jørgensen, Kåre I Birkeland, Reinhard W Holl, Josep Franch-Nadal, Navdeep Tangri, Jonathan E Shaw, Jenni Ilomäki, Avraham Karasik, Su-Yen Goh, Chern-En Chiang, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, Mikhail Kosiborod, Mikhail Kosiborod, Matthew A Cavender, John P Wilding, Kamlesh Khunti, Anna Norhammar, Kåre Birkeland, Marit Eika Jørgensen, Reinhard W. Holl, Carolyn SP Lam, Hanne Løvdal Gulseth, Bendix Carstensen, Esther Bollow, Josep Franch-Nadal, Luis Alberto García Rodríguez, Avraham Karasik, Navdeep Tangri, Shun Kohsaka, Dae Jung Kim, Jonathan Shaw, Suzanne Arnold, Su-Yen Goh, Peter Fenici, Johan Bodegård, Hungta Chen, Filip Surmont, Betina T. Blak, Eric T. Wittbrodt, Matthias Saathoff, Yusuke Noguchi, Donna Tan, Maro Williams, Hye Won Lee, Maya Greenbloom, Oksana Kaidanovich-Beilin, Khung Keong Yeo, Yong Mong Bee, Joan Khoo, Agnes Koong, Yee How Lau, Fei Gao, Wee Boon Tan, Hanis Abdul Kadir, Kyoung Hwa Ha, Jinhee Lee, Gabriel Chodick, Cheli Melzer-Cohen, Reid Whitlock, Lucia Cea-Soriano, Oscar Fernándex Cantero, Jordan A. Menzin, Matthew Guthrie, Jennie Ilomaki, Dianna Magliano
Journal: The Lancet Diabetes & Endocrinology (2020)
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study
Authors: Adam J Kucharski, Petra Klepac, Andrew J K Conlan, Stephen M Kissler, Maria L Tang, Hannah Fry, Julia R Gog, W John Edmunds, Jon C Emery, Graham Medley, James D Munday, Timothy W Russell, Quentin J Leclerc, Charlie Diamond, Simon R Procter, Amy Gimma, Fiona Yueqian Sun, Hamish P Gibbs, Alicia Rosello, Kevin van Zandvoort, Stéphane Hué, Sophie R Meakin, Arminder K Deol, Gwen Knight, Thibaut Jombart, Anna M Foss, Nikos I Bosse, Katherine E Atkins, Billy J Quilty, Rachel Lowe, Kiesha Prem, Stefan Flasche, Carl A B Pearson, Rein M G J Houben, Emily S Nightingale, Akira Endo, Damien C Tully, Yang Liu, Julian Villabona-Arenas, Kathleen O'Reilly, Sebastian Funk, Rosalind M Eggo, Mark Jit, Eleanor M Rees, Joel Hellewell, Samuel Clifford, Christopher I Jarvis, Sam Abbott, Megan Auzenbergs, Nicholas G Davies, David Simons
Journal: The Lancet Infectious Diseases (2020)
A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial
Authors: Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad-Reza Rafiyan, Salah-Eddin Al-Batran, Mirjam Tariverdian, Elke Jäger, Magnus von Knebel Doeberitz
Journal: Clinical Cancer Research (2020)

Abstract Purpose: DNA mismatch repair (MMR) deficiency is a hallmark of Lynch syndrome, the most common inherited cancer syndrome. MMR-deficient cancer cells accumulate numerous insertion/deletion mutations at microsatellites. Mutations of coding microsatellites (cMS) lead to the generation of immunogenic frameshift peptide (FSP) neoantigens. As the evolution of MMR-deficient cancers is triggered by mutations inactivating defined cMS-containing tumor suppressor genes, distinct FSP neoantigens are shared by most MMR-deficient cancers. To evaluate safety and immunogenicity of an FSP-based vaccine, we performed a clinical phase I/IIa trial (Micoryx). Patients and Methods: The trial comprised three cycles of four subcutaneous vaccinations (FSP neoantigens derived from mutant AIM2, HT001, TAF1B genes) mixed with Montanide ISA-51 VG over 6 months. Inclusion criteria were history of MMR-deficient colorectal cancer (UICC stage III or IV) and completion of chemotherapy. Phase I evaluated safety and toxicity as primary endpoint (six patients), phase IIa addressed cellular and humoral immune responses (16 patients). Results: Vaccine-induced humoral and cellular immune responses were observed in all patients vaccinated per protocol. Three patients developed grade 2 local injection site reactions. No vaccination-induced severe adverse events occurred. One heavily pretreated patient with bulky metastases showed stable disease and stable CEA levels over 7 months. Conclusions: FSP neoantigen vaccination is systemically well tolerated and consistently induces humoral and cellular immune responses, thus representing a promising novel approach for treatment and even prevention of MMR-deficient cancer.
SAT0173 A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2019 UPDATE OF THE JOINT EUROPEAN LEAGUE AGAINST RHEUMATISM AND EUROPEAN RENAL ASSOCIATION–EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE MANAGEMENT OF LUPUS NEPHRITIS
Authors: A. Fanouriakis, M. Kostopoulou, K. Cheema, G. Bertsias, D. Jayne, D. Boumpas
Journal: Annals of the Rheumatic Diseases (2020)

Background: Lupus nephritis (LN) affects ~ 40% of patients with systemic lupus erythematosus (SLE) and is associated with significant morbidity. New data has emerged since the publication of the EULAR/ERA-EDTA recommendations for the management of LN, involving a multidisciplinary panel of experts. Objectives: To analyze the current evidence, in order to inform the 2019 update of the EULAR/ERA-EDTA recommendations for the management of LN. Methods: According to the EULAR standardised operating procedures, a Medline systematic literature review (SLR) was performed, from January 2012 until 31 December 2018. The final level of evidence (LoE) and grading of recommendations considered the total body of evidence, including the LoE of the 2012 recommendations. Results: We identified 542 relevant articles. High-quality evidence supports the use of immunosuppressive treatment for class III and IV LN (LoE 1a) there is moderate quality evidence for immunosuppression in pure class V LN, with nephrotic-range proteinuria (LoE 2b). Treatment should aim for a 25% reduction in proteinuria at 3 months, 50% at 6 months and complete renal response (&lt; 500-700 mg/day) at 12 months (LoE 2a-2b). Strong evidence supports the use of mycophenolate mofetil/mycophenolic acid (MMF/MPA) or low-dose intravenous cyclophosphamide (CY) for the initial treatment of class III/IV LN (LoE 1a, Table ); Combination of tacrolimus with MMF/MPA and high-dose CY are alternatives in specific circumstances (LoE 1a, Table ). There is little evidence to guide optimal duration of immunosuppression in LN (LoE 3). In end-stage kidney disease due to LN, all methods of kidney replacement treatment have been used, but transplantation is accompanied by the most favourable outcomes (LoE 2b). Table. Randomized trials for induction therapy in LN Conclusion: There is high-quality evidence to guide the initial and subsequent phases of class III/IV LN treatment. There is low quality evidence to guide treatment of class V, monitoring and optimal duration of immunosuppression. Disclosure of Interests: : Antonis Fanouriakis Paid instructor for: Paid instructor for Enorasis, Amgen, Speakers bureau: Paid speaker for Roche, Genesis Pharma, Mylan, Myrto Kostopoulou: None declared, Kim Cheema: None declared, George Bertsias Grant/research support from: GSK, Consultant of: Novartis, David Jayne Grant/research support from: ChemoCentryx, GSK, Roche/Genentech, Sanofi-Genzyme, Consultant of: Astra-Zeneca, ChemoCentryx, GSK, InflaRx, Takeda, Insmed, Chugai, Boehringer-Ingelheim, Dimitrios Boumpas: None declared
AB0523 TAKAYASU ARTERITIS AND SACROILIITIS: A CASE-CONTROL STUDY
Authors: F. Regola, G. Bosio, F. Franceschini, P. Toniati
Journal: Annals of the Rheumatic Diseases (2020)

Background: A possible shared immunopathogenesis between Spondyloarthritis (SpA) and Takayasu Arteritis (TA) has been hypothesized and some clinical cases about SpA in TA patients have been reported (1). In clinical practice the diagnosis of sacroiliitis may be performed by X-ray, Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). In particular, CT findings of sacroiliitis include contour irregularities, joint space alterations, joint erosion, subcondral bone changes (osteoporosis or sclerosis), enthesitis, ankylosis. Meanwhile, TA patients performe routinely FDG-PET/CT scans for monitoring disease activity. Objectives: This study aims to understand if there is an increased incidence of sacroiliitis in TA patients. Methods: We collected retrospectively imaging data from FDG-PET/CT scans of 28 TA patients and 28 controls, matched for sex and age. Controls were selected among patients performing FDG-PET/CT in our Nuclear Medicine Unit, excluding patients with bone tumors, bone metastasis and thyroid cancers. The majority of controls were affected by lymphoma in complete remission. An expert rheumatologist read the CT-scans of sacroiliac joints. Results: No patients or controls demonstrated FDG-uptake in sacroiliac joints. In the control group we detected sacroiliac sclerosis in two cases: one due to degenerative changes, one to sacroiliitis (1/28, 4%). In the TA group four patients presented CT alterations suggestive for sacroiliitis: one bilateral erosion, one bilateral sclerosis, two monolateral sclerosis (4/28, 14%). One of these patients complained an inflammatory back pain. Conclusion: In our cohort of TA patients we demonstrated an increased prevalence of sacroiliitis, diagnosed by CT scan. Only one patient reported an inflammatory back pain, while three patients had radiological signs of previous sacroiliitis. These findings highlight the importance of looking for spondyloarthropathy in TA patients even if asymptomatic. References: [1]Guzel Esen S, Joint Bone Spine, 2019 Disclosure of Interests: None declared
<scp> <sup>18</sup> F‐FDG PET </scp> / <scp>CT</scp> brain glucose metabolism as a marker of different types of depression comorbidity in chronic heart failure patients with impaired systolic function
Authors: Vassiliki Lyra, John Parissis, Maria Kallergi, Emmanouil Rizos, Gerasimos Filippatos, Dimitrios Kremastinos, Sofia Chatziioannou
Journal: European Journal of Heart Failure (2020)
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Authors: Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
Journal: The Lancet. Gastroenterology & hepatology (2020)
Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology
Authors: Antonio Saviano, Neil C. Henderson, Thomas F. Baumert
Journal: Journal of Hepatology (2020)

Transcriptome analysis enables the study of gene expression in human tissues and is a valuable tool to characterise liver function and gene expression dynamics during liver disease, as well as to identify prognostic markers or signatures, and to facilitate discovery of new therapeutic targets. In contrast to whole tissue RNA sequencing analysis, single-cell RNA-sequencing (scRNA-seq) and spatial transcriptomics enables the study of transcriptional activity at the single cell or spatial level. ScRNA-seq has paved the way for the discovery of previously unknown cell types and subtypes in normal and diseased liver, facilitating the study of rare cells (such as liver progenitor cells) and the functional roles of non-parenchymal cells in chronic liver disease and cancer. By adding spatial information to scRNA-seq data, spatial transcriptomics has transformed our understanding of tissue functional organisation and cell-to-cell interactions in situ. These approaches have recently been applied to investigate liver regeneration, organisation and function of hepatocytes and non-parenchymal cells, and to profile the single cell landscape of chronic liver diseases and cancer. Herein, we review the principles and technologies behind scRNA-seq and spatial transcriptomic approaches, highlighting the recent discoveries and novel insights these methodologies have yielded in both liver physiology and disease biology.
Abstract 2782: Erectile Dysfunction Predicts High Risk Findings on Myocardial Perfusion SPECT Imaging in Men without Prior Heart Disease
Authors: Justin Weiner, James K Min, S Nasir Ghani, Linda A Taillon, Kim A Williams, R Parker Ward
Journal: Circulation (2006)

Background: Erectile dysfunction (ED) has recently been associated with a future risk of myocardial infarction (MI) in men without prior coronary artery disease (CAD), yet the benefit of stress tes...
Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome
Authors: Hiroshi Kikuchi, Nako Maishi, Dorcas A. Annan, Mohammad Towfik Alam, Randa Ibrahim Hassan Dawood, Masumi Sato, Masahiro Morimoto, Ryo Takeda, Keita Ishizuka, Ryuji Matsumoto, Tomoshige Akino, Kunihiko Tsuchiya, Takashige Abe, Takahiro Osawa, Naoto Miyajima, Satoru Maruyama, Toru Harabayashi, Manabu Azuma, Katsushige Yamashiro, Kaname Ameda, Akira Kashiwagi, Yoshihiro Matsuno, Yasuhiro Hida, Nobuo Shinohara, Kyoko Hida
Journal: Cancer Research (2020)

Abstract Tumor endothelial cells (TEC) lining tumor blood vessels actively contribute to tumor progression and metastasis. In addition to tumor cells, TEC may develop drug resistance during cancer treatment, allowing the tumor cells to survive chemotherapy and metastasize. We previously reported that TECs resist paclitaxel treatment via upregulation of ABCB1. However, whether TEC phenotypes are altered by anticancer drugs remains to be clarified. Here, we show that ABCB1 expression increases after chemotherapy in urothelial carcinoma cases. The ratio of ABCB1-positive TEC before and after first-line chemotherapy in urothelial carcinoma tissues (n = 66) was analyzed by ABCB1 and CD31 immunostaining. In 42 cases (64%), this ratio increased after first-line chemotherapy. Chemotherapy elevated ABCB1 expression in endothelial cells by increasing tumor IL8 secretion. In clinical cases, ABCB1 expression in TEC correlated with IL8 expression in tumor cells after first-line chemotherapy, leading to poor prognosis. In vivo, the ABCB1 inhibitor combined with paclitaxel reduced tumor growth and metastasis compared with paclitaxel alone. Chemotherapy is suggested to cause inflammatory changes in tumors, inducing ABCB1 expression in TEC and conferring drug resistance. Overall, these findings indicate that TEC can survive during chemotherapy and provide a gateway for cancer metastasis. Targeting ABCB1 in TEC represents a novel strategy to overcome cancer drug resistance. Significance: These findings show that inhibition of ABCB1 in tumor endothelial cells may improve clinical outcome, where ABCB1 expression contributes to drug resistance and metastasis following first-line chemotherapy.
Tinea incognito infection with <i>Trichophyton erinacei</i> from a pet hedgehog
Authors: B. Yin, X. Ran, C. Zhang, Z. Xie, Y. Ran, L. Fu, S. Pradhan
Journal: British Journal of Dermatology (2020)

Dear Editor, A 21-year-old woman presented with a pruritic erythematous area and pustules on her right palm for 5 days (a). She was treated with topical steroids without improvement. Her contact with a pet hedgehog suggested tinea incognito (b).1 This was confirmed by cultures from the lesion and the pet's quill. Microscopic examination of two slide cultures with fluorescence staining revealed similar teardrop-shaped microconidia along the sides of the hyphae. Scanning electron microscopy of a quill demonstrated dense biofilms of hyphae (c). Trichophyton erinacei (GenBank MN939685 and MT002727) was identified by sequencing. The zoophilic dermatophytes induce marked dermal inflammatory responses, which may lead to misdiagnosis.
Derivation and validation of genome-wide polygenic score for urinary tract stone diagnosis
Authors: Ishan Paranjpe, Noah Tsao, Renae Judy, Manish Paranjpe, Kumardeep Chaudhary, Derek Klarin, Iain Forrest, Ross O’Hagan, Arjun Kapoor, John Pfail, Suraj Jaladanki, Fayzan Chaudhry, Akhil Vaid, Phan Q. Duy, John Cijiang He, Benjamin S. Glicksberg, Steven G. Coca, Mantu Gupta, Ron Do, Scott M. Damrauer, Girish N. Nadkarni
Journal: Kidney International (2020)
PCSK9のモノクローナル抗体であるエボロクマブ(AMG145)の心血管高リスクの高コレステロール血症でスタチン治療を受けている日本人患者における効果 第2相湯川研究からの最初の結果 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Hirayama Atsushi, Honarpour Narimon, Yoshida Masayuki, Yamashita Shizuya, Huang Fannie, M Wasserman Scott, Teramoto Tamio
Journal: Circulation (2014)
Neoadjuvant Checkpoint Inhibitor Therapy for Merkel Cell Carcinoma
Authors: Andrew S. Brohl, Vernon K. Sondak
Journal: Journal of Clinical Oncology (2020)

A 78-year-old man presented with rapidly enlarging lymph nodes in the right preauricular region and neck. Needle biopsy revealed a cytokeratin 20-positive, high-grade neuroendocrine neoplasm consistent with Merkel cell carcinoma (MCC). Cross-sectional imaging disclosed a 5.2-cm intraparotid mass and extensive adenopathy in the ipsilateral cervical and submental chains (Figs 1A and 1C), without distant metastatic disease. A skin examination did not reveal a primary lesion (hence, stage IIIA, T0N1bM0). The patient's history was notable for hypertension, diet-controlled diabetes type II, high cholesterol, and a past history of numerous cutaneous basal and squamous cell carcinomas. He was quite active but reported discomfort from the bulk of the tumors. The patient was evaluated by the surgical oncology team, who believed that the parotid mass and cervical adenopathy were technically resectable but that resection carried a substantial risk of morbidity because of the potential need to sacrifice the facial and/or spinal accessory nerves and because of a likely margin-positive (R1 or R2) result. He was referred to the medical oncology team to discuss management options for regionally advanced, "borderline-resectable" MCC.
Critical reviews of immunotheranostics
Authors: Xiaoyuan Chen, Mingnan Chen
Journal: Theranostics (2020)

Immunity is the most critical and well-regulated protection to the body. Immunity is implicated in a wide range of diseases and serves as the foundation for immunotherapy. Immunotheranostics is the idea of improving immunotherapy through the organic integration of therapeutic, diagnostic, and screening technologies. This special issue collects reviews and opinions from prominent contributors in the immunotheranostic field who represent highly diversified research expertise. The immunotherapeutics discussed in this issue range from small molecules, peptides, antibodies, nanoparticles, and to cells. Discussions from the therapeutic development perspective are accompanied by opinions from the biology and medicine aspects. Further, there are reviews about different types of imaging technologies and their applications in immunotherapy. Lastly, one review raises attention to mass spectrometry for its utilization in the diagnosis and assessment for immunotherapy. In summary, this special issue is a showcase for what is happening in immunotheranostics. Moreover, it is also a justified wish list for what should and will happen in immunotheranostics.